JP2002542296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542296A5 JP2002542296A5 JP2000613446A JP2000613446A JP2002542296A5 JP 2002542296 A5 JP2002542296 A5 JP 2002542296A5 JP 2000613446 A JP2000613446 A JP 2000613446A JP 2000613446 A JP2000613446 A JP 2000613446A JP 2002542296 A5 JP2002542296 A5 JP 2002542296A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- use according
- hematocrit
- erythropoietin
- cisplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/300,124 | 1999-04-27 | ||
| US09/300,124 US6171620B1 (en) | 1999-04-27 | 1999-04-27 | Method of enhancing the efficacy of anti-tumor agents |
| PCT/US2000/011000 WO2000064455A1 (en) | 1999-04-27 | 2000-04-24 | Method of enhancing the efficacy of anti-tumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542296A JP2002542296A (ja) | 2002-12-10 |
| JP2002542296A5 true JP2002542296A5 (https=) | 2007-06-28 |
Family
ID=23157813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000613446A Pending JP2002542296A (ja) | 1999-04-27 | 2000-04-24 | 抗腫瘍剤の効力を増大させる方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6171620B1 (https=) |
| EP (1) | EP1212068A4 (https=) |
| JP (1) | JP2002542296A (https=) |
| KR (1) | KR100693796B1 (https=) |
| CN (1) | CN1188137C (https=) |
| AU (1) | AU781301B2 (https=) |
| BG (1) | BG64940B1 (https=) |
| BR (1) | BR0010082A (https=) |
| CA (1) | CA2368618C (https=) |
| HU (1) | HUP0200840A3 (https=) |
| IL (1) | IL146012A0 (https=) |
| MX (1) | MXPA01010899A (https=) |
| NO (1) | NO20015227L (https=) |
| NZ (1) | NZ514521A (https=) |
| PL (1) | PL350918A1 (https=) |
| RU (1) | RU2271829C2 (https=) |
| WO (1) | WO2000064455A1 (https=) |
| ZA (1) | ZA200108012B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2232613T3 (es) | 2000-04-26 | 2005-06-01 | Cellegy Pharmaceuticals, Inc | Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno. |
| US7678391B2 (en) * | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| US20050142217A1 (en) * | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| DE60332358D1 (de) * | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| CA2811272C (en) | 2003-04-08 | 2016-12-20 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
| DE10361813A1 (de) * | 2003-12-30 | 2005-09-08 | Bionethos Holding Gmbh | Verfahren zur Regeneration von Gewebe |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| ES2714198T3 (es) * | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
| EP2565195B1 (en) | 2007-03-29 | 2015-05-06 | Wyeth LLC | Peripheral opioid receptor and antagonists and uses thereof |
| JP2010522756A (ja) | 2007-03-29 | 2010-07-08 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 結晶形およびその使用 |
| PL2137191T3 (pl) | 2007-03-29 | 2016-12-30 | Antagoniści obwodowego receptora opioidowego i ich zastosowania | |
| AU2008349873B2 (en) | 2008-02-06 | 2014-02-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone |
| CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| US20110142834A1 (en) * | 2008-05-15 | 2011-06-16 | Edison Pharmaceuticals, Inc. | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| PL230756B1 (pl) * | 2015-09-11 | 2018-12-31 | Univ Medyczny W Bialymstoku | Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu |
| JPWO2019083023A1 (ja) * | 2017-10-26 | 2020-11-12 | 国立大学法人 筑波大学 | 癌の治療に使用するための組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
| JP2632014B2 (ja) * | 1988-03-03 | 1997-07-16 | 中外製薬株式会社 | 骨髄機能障害性貧血治療剤 |
| RU2111750C1 (ru) * | 1995-02-23 | 1998-05-27 | Институт элементоорганических соединений РАН | Модификатор для противоопухолевой терапии |
| JPH1067678A (ja) * | 1996-06-20 | 1998-03-10 | Chugai Pharmaceut Co Ltd | 肝疾患治療用医薬組成物 |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
-
1999
- 1999-04-27 US US09/300,124 patent/US6171620B1/en not_active Expired - Fee Related
-
2000
- 2000-04-24 RU RU2001131894/14A patent/RU2271829C2/ru not_active IP Right Cessation
- 2000-04-24 NZ NZ514521A patent/NZ514521A/en not_active IP Right Cessation
- 2000-04-24 JP JP2000613446A patent/JP2002542296A/ja active Pending
- 2000-04-24 HU HU0200840A patent/HUP0200840A3/hu unknown
- 2000-04-24 IL IL14601200A patent/IL146012A0/xx unknown
- 2000-04-24 PL PL00350918A patent/PL350918A1/xx not_active Application Discontinuation
- 2000-04-24 CA CA2368618A patent/CA2368618C/en not_active Expired - Fee Related
- 2000-04-24 CN CNB008065659A patent/CN1188137C/zh not_active Expired - Fee Related
- 2000-04-24 MX MXPA01010899A patent/MXPA01010899A/es active IP Right Grant
- 2000-04-24 BR BR0010082-0A patent/BR0010082A/pt not_active Application Discontinuation
- 2000-04-24 KR KR1020017012929A patent/KR100693796B1/ko not_active Expired - Fee Related
- 2000-04-24 EP EP00926315A patent/EP1212068A4/en not_active Withdrawn
- 2000-04-24 AU AU44863/00A patent/AU781301B2/en not_active Ceased
- 2000-04-24 WO PCT/US2000/011000 patent/WO2000064455A1/en not_active Ceased
- 2000-12-19 US US09/740,501 patent/US6426094B2/en not_active Expired - Fee Related
-
2001
- 2001-09-28 ZA ZA200108012A patent/ZA200108012B/xx unknown
- 2001-10-25 NO NO20015227A patent/NO20015227L/no not_active Application Discontinuation
- 2001-10-26 BG BG106057A patent/BG64940B1/bg unknown
-
2002
- 2002-07-26 US US10/206,533 patent/US6620779B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002542296A5 (https=) | ||
| BR0207378A (pt) | Tratamento de câncer | |
| JP2004525194A5 (https=) | ||
| AR022974A1 (es) | Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble. | |
| NZ621449A (en) | Treatment with anti-vegf antibodies | |
| IL179714A (en) | Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation | |
| JP2002506648A5 (https=) | ||
| WO2003013541A8 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| DK1196146T3 (da) | Pulverpartikler med glat overflade til anvendelse i inhalationsterapi | |
| WO2001066123A3 (en) | Composition consisting of phy906 and chemotherapeutic agents | |
| ATE486840T1 (de) | Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür | |
| JP2001522820A5 (https=) | ||
| SE7611379L (sv) | Antihypertensiva medel | |
| JP2006514116A5 (https=) | ||
| WO2002102306A8 (en) | Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy | |
| WO2002056835A3 (en) | Anticancer treatment using triptolide prodrugs | |
| AUPQ879500A0 (en) | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease | |
| MXPA03008423A (es) | Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias. | |
| WO2001062235A3 (en) | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | |
| UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
| ATE417608T1 (de) | Arzneizusammensetzungen enthaltend modafinilverbindungen | |
| WO2003007914A3 (en) | Biocompatible polymer containing composition for treatment of prostate cancers | |
| JP2009516719A5 (https=) | ||
| AU4789099A (en) | Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents | |
| Lunniss | Archaeology at Salango, Ecuador: an Engoroy ceremonial site on the south coast of Manabí |